Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

96 Well Microplates with 3D Epoxy Surface

Published: Monday, August 12, 2013
Last Updated: Monday, August 12, 2013
Bookmark and Share
Ideal platform for covalent binding of biomolecules.

Greiner Bio-One has developed 96 well microplates with a 3D epoxy surface in collaboration with its longstanding cooperation partner PolyAn.

The 3D epoxy surface is the ideal platform for covalent binding of proteins, peptides, DNA and oligonucleotides.

The three-dimensional functional matrix allows the development of covalent binding of nucleophiles to the plate surface without complex coupling chemistry.

The structure of the matrix, which has a thickness of up to 50 nm, also reduces unspecific binding to a minimum.

The three-dimensional epoxy 96 well microplates are used mainly if adsorptive binding of peptides or oligonucleotides, for example, to high/medium binding surfaces is ineffective or the binding strength is not sufficient.

Areas of application include detection methods such as ELISA, ELI-Spot, protein and peptide arrays and DNA binding.

The 3D epoxy surface is chemically and mechanically highly robust and features particularly homogeneous surface functionalisation.

The microplates with a 3D epoxy surface are free of detectable DNases and RNases. The shelf life at room temperature is two years.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Big Plans and 40 Years of Experience
Rudi Vollmer becomes new Technical Managing Director of Greiner Bio-One GmbH, responsible for production and technology.
Tuesday, June 30, 2015
Tradition Meets Innovation -­ Greiner Bio-One Celebrates 50 Successful Years
Company now has over 1,700 employees spread across seven production facilities.
Friday, December 13, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Angina Drug Could Inform A New Strategy To Fight Cryptococcosis
A drug, more commonly used in the treatment of angina, could be the focus of a new strategy in fighting the fatal fungal infection cryptococcosis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!